Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRASG12C-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies

Fig. 3

Kaplan–Meier plots of survival curves in KRASG12C-mutated metastatic CRC patients treated with IBI351 monotherapy. Progression-free survival (a) and overall survival (b) in the overall population. Progression-free survival (c) and overall survival (d) in patients treated with IBI351 at RP2D (600 mg BID). Progression-free survival (e) and overall survival (f) in patients who had ≥2 lines of prior treatment treated with IBI351 at RP2D. BID twice daily, RP2D recommended phase II dose, CRC colorectal cancer, CI confidence interval, PFS progression-free survival, OS overall survival, NR not reached. Bars indicate censored data

Back to article page